Analysis of Milrinon (Shim-pack Scepter C18-120)

Significance of the topic

The quantification of milrinone, a phosphodiesterase 3 inhibitor used in heart failure management, is critical for ensuring drug safety and efficacy. A reliable analytical method allows pharmaceutical manufacturers and quality control laboratories to monitor active ingredient levels and impurities, supporting regulatory compliance and patient safety.

Objectives and overview of the study

This application note describes the development and validation of a reversed-phase high-performance liquid chromatography (RP-HPLC) method to separate and quantify milrinone and its two related impurities. The study aims to demonstrate system suitability, peak resolution, and reproducibility under isocratic conditions using Shimadzu’s Shim-pack Scepter C18-120 column.

Methodology and used instrumentation

The method employs isocratic elution with a mobile phase consisting of water, methanol, and sodium borate buffer (pH 9.0) in a 725 : 250 : 25 ratio, with 20 % sodium hydroxide solution. Key parameters include:

• Column: Shim-pack Scepter C18-120 (250 mm × 4.6 mm I.D., 5 µm)
• Flow rate: 1.0 mL/min
• Column temperature: 25 °C
• Injection volume: 20 µL
• Detection: PDA UV at 254 nm
• Sample container: LabTotal™ vial for LC/LCMS

Key results and discussion

Chromatograms of both the system suitability solution and milrinone sample demonstrate clear baseline separation of milrinone and its two impurities within a 35-minute runtime. The system suitability mix shows well-defined peaks with consistent retention times and resolution values exceeding acceptance criteria. Reproducible peak shapes and retention data highlight the method’s robustness.

Benefits and practical applications

The presented RP-HPLC method offers:

• High specificity for milrinone and related impurities
• Simple isocratic operation conducive to routine QC workflows
• Reproducibility in retention times and peak areas
• Compatibility with standard UV detection systems

Implementation in pharmaceutical QC laboratories ensures adherence to pharmacopoeial standards and efficient batch release testing.

Future trends and potential uses

Advancements may include coupling with mass spectrometry for enhanced impurity identification, miniaturization with UHPLC columns for shorter analysis times, and integration into automated workflows for high-throughput screening. Real-time monitoring and online data analytics could further optimize process control in pharmaceutical manufacturing.

Conclusion

The developed Shim-pack Scepter C18-120 method provides a reliable, reproducible, and easy-to-operate RP-HPLC procedure for the analysis of milrinone and its impurities. It meets the stringent requirements of pharmaceutical quality control and supports efficient regulatory compliance.